In type 2 diabetes with increased CV risk, tirzepatide reduced HbA1c vs. glargine at 52 wk. Singh M. Ann Intern Med 2022 Mar 1. doi: 10.7326/J22-0009.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Singh M. In type 2 diabetes with increased CV risk, tirzepatide reduced HbA1c vs. glargine at 52 wk. Ann Intern Med 2022 Mar 1. doi: 10.7326/J22-0009.
PMID: 35226523